DB06539ExperimentalSmall molecule
The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor. It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but...
- Primary indication
- Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).Curator reviewed
- Also known as
- 1,3-DIHYDRO-1-METHYL-5-((4-((2S,4R)-TETRAHYDRO-4-HYDROXY-2-METHYL-2H-PYRAN-4-YL)-2-THIENYL)THIO)-2H-INDOL-2-ONE · 2H-INDOL-2-ONE, 1,3-DIHYDRO-1-METHYL-5-((4-((2S,4R)-TETRAHYDRO-4-HYDROXY-2-METHYL-2H-PYRAN-4-YL)-2-THIENYL)THIO)- · 2H-INDOL-2-ONE, 1,3-DIHYDRO-1-METHYL-5-((4-(TETRAHYDRO-4-HYDROXY-2-METHYL-2H-PYRAN-4-YL)-2-THIENYL)THIO)-, (2S-TRANS)- · 5-(4-((2S,4R)-4-HYDROXY-2-METHYLOXAN-4-YL)THIOPHEN-2-YL)SULFANYL-1-METHYL-3H-INDOL-2-ONE
- Code names
- ZD-4407
Resolves to
Compound
Which companies are running trials of ZD4407, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account